Zobrazeno 1 - 2
of 2
pro vyhledávání: '"therapeutic use [Anti-Dyskinesia Agents]"'
Autor:
Ludger Schöls, Wolfgang Nachbauer, Pablo Celnik, Roxana G. Burciu, Katharina Feil, Dagmar Timmann, I. Miyai, S Boesch, Julian Teufel, J. Claaßen, Michael Strupp, Roger Kalla, Winfried Ilg, Matthis Synofzik, Amy J. Bastian
Publikováno v:
The Cerebellum 13(2), 248-268 (2013). doi:10.1007/s12311-013-0531-6
Treatment of motor symptoms of degenerative cerebellar ataxia remains difficult. Yet there are recent developments that are likely to lead to significant improvements in the future. Most desirable would be a causative treatment of the underlying cere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d71401ed12cc3e04c1fb1d8442c09a95
https://doi.org/10.1007/s12311-013-0531-6
https://doi.org/10.1007/s12311-013-0531-6
Publikováno v:
CNS drugs 28(12), 1155-1184 (2014). doi:10.1007/s40263-014-0205-z
l-Dopa-induced dyskinesias (LID) are the most common adverse effects of long-term dopaminergic therapy in Parkinson’s disease (PD). However, the exact mechanisms underlying dyskinesia are still unclear. For a long time, nigrostriatal degeneration a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219f60307f131ecdf2bf208550f4d7c7
